Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.
Voskaridou
Ersi
E
Christoulas
Dimitrios
D
Konstantinidou
Marialena
M
Tsiftsakis
Evangelos
E
Alexakos
Panagiotis
P
Terpos
Evangelos
E
D000328:Adult; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology*; D010146:Pain; D013789:Thalassemia / Q000097:blood / Q000150:complications*; D013997:Time Factors; D000077211:Zoledronic Acid
D015415:Biomarkers; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid